JANUARY 1 – DECEMBER 31, 2007
• Net sales for the period amounted to SEK 64.7 M (69.0)
• Profit after tax was SEK 19.8 M (36.2)
• Earnings per share after tax amounted to SEK 1.73 (3.17)
• Operating profit amounted to SEK 25.8 M (33.5)
• Cash flow from operating activities amounted to SEK 37.9 M (30.1)
• Collaboration agreement with Varian Medical Systems was signed in May
• Collaboration agreement with TomoTherapy was signed in August
• COMPASS® received FDA clearance and was launched in December.
• Board of Directors proposes a dividend of SEK 0.50 (0.00) per share
• Board of Directors proposes 3:1 share split
”We are now in a phase of intensive development. During 2007 we expanded from three to five partners and increased the number of employees in research and development by three quarters. In December, we also entered an entirely new market segment with the launch of COMPASS®,” says Johan Löf, CEO of RaySearch.
“Financially, 2007 was a moderate year since the new products and partnerships had not yet begun to contribute to earnings positively. But with eight products on the market and more than fifteen new products in development, the conditions for solid growth are favorable. I am therefore highly optimistic about the future,” concludes Johan Löf.
FOR FURTHER INFORMATION, CONTACT:
Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com
RaySearch Laboratories AB (publ)
Corp. Reg. No. 556322-6157
Sveavägen 25
SE-111 34 Stockholm
Press releases
